d3_skipII_tte: Expected probability to go to phase III for time-to-event...

In Sterniii3/drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning

Expected probability to go to phase III for time-to-event outcomes

Description

If choosing skipII = TRUE, the program calculates the expected utility for the case when phase II is skipped and compares it to the situation when phase II is not skipped. This function calculates the expected sample size for phase III for time-to-event outcomes using a median prior.

Usage

d3_skipII_tte(alpha, beta, median_prior)

Arguments

alpha	significance level
beta	1-beta power for calculation of sample size for phase III
median_prior	the median_prior is given as -log(hr1), the assumed true treatment effect

Value

The output of the functions d3_skipII_tte() is the expected number of events in phase III when skipping phase II.

Examples

res <- d3_skipII_tte(alpha = 0.05, beta = 0.1, median_prior = 0.35)

Sterniii3/drugdevelopR documentation built on Jan. 26, 2024, 6:17 a.m.